Investigator-initiated multinational early-stage innovative clinical trials for paediatric cancer - Cancer Mission

HaDEA has published the Cancer Mission call Supporting the implementation of the Cancer Mission (HORIZON-MISS-2025-02).

Proposals under topic HORIZON-MISS-2025-02-CANCER-04 should address all of the following:

• Design and conduct innovative investigator-initiated multinational early-stage clinical trials, (phase 1 and 1/2) to accelerate the development of safe, effective, targeted cancer treatments for children and/or adolescents with cancer. Focus should be on cancers with poor prognosis (e.g. with a 5-year overall survival less than 50% from time of diagnosis) at any stage of the disease and for any type. Trials should take into account socio-economic and biological stratification. All data should be disaggregated by sex, gender, age and other relevant variables;
• Develop innovative clinical tools (companion diagnostics) to assess tumour response, tailored to childhood and adolescent cancers, enabling an accurate evaluation of treatment outcomes, monitoring of long-term effects of treatment, and identification of potential risks such as second cancers, thereby improving overall patient care;
• Ultimately, provide scientific evidence to deliver affordable and accessible treatments for children and adolescents with cancer to be implemented by healthcare systems at the level of local communities, European regions, Member States and Associated Countries;
• All datasets produced should be described with metadata records in the EU dataset catalogue of the European Health Data Space, while all tools and models should take advantage of current European research infrastructures, should follow the principles of open science and made available through the future UNCAN.eu platform.

Interested parties can find more information and apply on the Funding and Tenders Portal.